Polymeric micro- and nanoparticles for immune modulation

Biomaterials Science

Volumn 7, Issue 1, 2019, Pages 14-30

  Ben Akiva, Elana ^a   Est Witte, Savannah ^a   Meyer, Randall A ^a   Rhodes, Kelly R ^a   Green, Jordan J ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIODEGRADABLE POLYMERS; CELL MEMBRANES; CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASES; IMMUNE SYSTEM; MONOCLONAL ANTIBODIES;

CELL SURFACE RECEPTORS; IMMUNOMODULATORY AGENTS; MICRO AND NANO-PARTICLE; NANOPARTICULATE SYSTEM; PARTICULATE SYSTEMS; POLYMERIC PARTICLES; SMALL-MOLECULE DRUGS; TRANSPLANT REJECTION;

TARGETED DRUG DELIVERY;

DRUG CARRIER; IMMUNOLOGIC FACTOR; NANOPARTICLE; POLYMER;

ANIMAL; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; NATURAL KILLER CELL; PROCEDURES; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; KILLER CELLS, NATURAL; NANOPARTICLES; POLYMERS; T-LYMPHOCYTES;

EID: 85058764416     PISSN: 20474830     EISSN: 20474849     Source Type: Journal    
DOI: 10.1039/c8bm01285g     Document Type: Review

References (149)

1. C. Wang Y. Ye Q. Hu A. Bellotti Z. Gu Tailoring biomaterials for cancer immunotherapy: Emerging trends and future outlook Adv. Mater. 2017 29 1606036
2. R. Klippstein D. Pozo Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies Nanomedicine 2010 6 523 529
3. A. K. Shakya and K. S. Nandakumar, Biomaterials for Induction and Treatment of Autoimmunity, in Advances in Biomaterials for Biomedical Applications, Springer, 2017, pp. 167-184
4. M. Rahmati, C. P. Pennisi, A. Mobasheri and M. Mozafari, Bioengineered Scaffolds for Stem Cell Applications in Tissue Engineering and Regenerative Medicine, 2018
5. A. B. Gardner S. K. Lee E. C. Woods A. P. Acharya Biomaterials-based modulation of the immune system BioMed Res. Int. 2013 2013 732182
6. S. Franz S. Rammelt D. Scharnweber J. C. Simon Immune responses to implants-a review of the implications for the design of immunomodulatory biomaterials Biomaterials 2011 32 6692 6709
7. J. J. Moon B. Huang D. J. Irvine Engineering nano- and microparticles to tune immunity Adv. Mater. 2012 24 3724 3746
8. E. Blanco H. Shen M. Ferrari Principles of nanoparticle design for overcoming biological barriers to drug delivery Nat. Biotechnol. 2015 33 941
9. N. Kamaly B. Yameen J. Wu O. C. Farokhzad Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release Chem. Rev. 2016 116 2602 2663
10. R. A. Meyer J. C. Sunshine J. J. Green Biomimetic particles as therapeutics Trends Biotechnol. 2015 33 514 524
11. J. Sunshine J. M. Taube PD-1/PD-L1 inhibitors Curr. Opin. Pharmacol. 2015 23 32 38
12. G. R. Burmester et al., Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis Arthritis Rheumatol. 2018 70 679 689
13. F. DeStefano, E. S. Weintraub and R. T. Chen, Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study, 2018
14. H. Caspard et al., Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States Vaccine 2016 34 77 82
15. J. Li S. G. Kim J. Blenis Rapamycin: one drug, many effects Cell Metab. 2014 19 373 379
16. J. L. Adams J. Smothers R. Srinivasan A. Hoos Big opportunities for small molecules in immuno-oncology Nat. Rev. Drug Discovery 2015 14 603
17. S. Y. Tzeng J. J. Green Polymeric Nucleic Acid Delivery for Immunoengineering Curr. Opin. Biomed. Eng. 2018
18. C.-Y. Lin et al., Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases Hum. Vaccines Immunother. 2015 11 650 656
19. A. Bolhassani et al., Polymeric nanoparticles Hum. Vaccines Immunother. 2014 10 321 332
20. D. S. Vinay et al., Immune evasion in cancer: Mechanistic basis and therapeutic strategies Semin. Cancer Biol. 2015 35 S185 S198
21. T. Chanmee P. Ontong K. Konno N. Itano Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment Cancers 2014 6 1670 1690
22. K. K. Ahmed S. M. Geary A. K. Salem Applying biodegradable particles to enhance cancer vaccine efficacy Immunol. Res. 2014 59 220 228
23. S. T. Reddy et al., Exploiting lymphatic transport and complement activation in nanoparticle vaccines Nat. Biotechnol. 2007 25 1159
24. I. Melero et al., Therapeutic vaccines for cancer: an overview of clinical trials Nat. Rev. Clin. Oncol. 2014 11 509
25. C. Mesa L. E. Fernández Challenges facing adjuvants for cancer immunotherapy Immunol. Cell Biol. 2004 82 644 650
26. S. Awate L. Babiuk G. Mutwiri Mechanisms of Action of Adjuvants Front. Immunol. 2013 4 114
27. K. K. Ahmed S. M. Geary A. K. Salem Development and Evaluation of Biodegradable Particles Co-loaded with Antigen and the Toll-like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine J. Pharm. Sci. 2016 105 1173 1179
28. S. Hamdy et al., Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles J. Biomed. Mater. Res., Part A 2007 81A 652 662
29. S. Hamdy et al., Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity Vaccine 2008 26 5046 5057
30. Z. Zhang et al., Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery Biomaterials 2011 32 3666 3678
31. P. Elamanchili C. M. E. Lutsiak S. Hamdy M. Diwan J. Samuel "Pathogen-Mimicking" Nanoparticles for Vaccine Delivery to Dendritic Cells J. Immunother. 2007 30 378 395
32. C. M. Jewell S. C. Bustamante López D. J. Irvine In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles Proc. Natl. Acad. Sci. 2011 108 15745 15750
33. X. Q. Zhang C. E. Dahle G. J. Weiner A. K. Salem A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles∗∗Xue-Qing Zhang and Christopher E. Dahle contributed equally to this work J. Pharm. Sci. 2007 96 3283 3292
34. A. Bershteyn et al., Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine J. Controlled Release 2012 157 354 365
35. R. H. Fang et al., Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery Nano Lett. 2014 14 2181 2188
36. Z. Luo et al., Cationic polypeptide micelle-based antigen delivery system: A simple and robust adjuvant to improve vaccine efficacy J. Controlled Release 2013 170 259 267
37. H. Kim T. Uto T. Akagi M. Baba M. Akashi Amphiphilic Poly(Amino Acid) Nanoparticles Induce Size-Dependent Dendritic Cell Maturation Adv. Funct. Mater. 2010 20 3925 3931
38. V. B. Joshi S. M. Geary A. K. Salem Biodegradable Particles as Vaccine Delivery Systems: Size Matters AAPS J. 2013 15 85 94
39. S. T. Reddy A. Rehor H. G. Schmoekel J. A. Hubbell M. A. Swartz In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles J. Controlled Release 2006 112 26 34
40. V. Manolova et al., Nanoparticles target distinct dendritic cell populations according to their size Eur. J. Immunol. 2008 38 1404 1413
41. S. N. Thomas E. Vokali A. W. Lund J. A. Hubbell M. A. Swartz Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response Biomaterials 2014 35 814 824
42. Y. Guo et al., Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma ACS Nano 2015 9 6918 6933
43. L. J. Cruz et al., Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro J. Controlled Release 2010 144 118 126
44. S. S. Saluja et al., Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen Int. J. Nanomed. 2014 9 5231 5246
45. R. A. Rosalia et al., CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses Biomaterials 2015 40 88 97
46. L. J. Cruz et al., Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study J. Controlled Release 2014 192 209 218
47. T. Chanmee P. Ontong K. Konno N. Itano Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment Cancers 2014 6 1670 1690
48. R. Noy J. W. Pollard Tumor-Associated Macrophages: From Mechanisms to Therapy Immunity 2014 41 49 61
49. M. J. Ernsting et al., Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle J. Controlled Release 2015 206 122 130
50. M. Niu et al., Biodistribution and in Vivo Activities of Tumor-Associated Macrophage-Targeting Nanoparticles Incorporated with Doxorubicin Mol. Pharm. 2014 11 4425 4436
51. M. Niu S. Valdes Y. W. Naguib S. D. Hursting Z. Cui Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer Mol. Pharm. 2016 13 1833 1842
52. A.-K. Fuchs et al., Carboxyl- and amino-functionalized polystyrene nanoparticles differentially affect the polarization profile of M1 and M2 macrophage subsets Biomaterials 2016 85 78 87
53. Y. Wang et al., Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment Biomaterials 2017 112 153 163
54. Y. J. Kwon E. James N. Shastri J. M. Frechet In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles Proc. Natl. Acad. Sci. U. S. A. 2005 102 18264 18268
55. A. Bandyopadhyay R. L. Fine S. Demento L. K. Bockenstedt T. M. Fahmy The impact of nanoparticle ligand density on dendritic-cell targeted vaccines Biomaterials 2011 32 3094 3105
56. G. Schreibelt et al., The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells Blood 2012 119 2284 2292
57. O. P. Joffre D. Sancho S. Zelenay A. M. Keller C. Reis e Sousa Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A Eur. J. Immunol. 2010 40 1255 1265
58. S. Kanno A. Furuyama S. Hirano A murine scavenger receptor MARCO recognizes polystyrene nanoparticles Toxicol. Sci. 2007 97 398 406
59. S. Prasad D. Xu S. D. Miller Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes Rev. Diabetes Stud. 2012 9 319 327
60. S. D. Miller R. P. Wetzig H. N. Claman The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells J. Exp. Med. 1979 149 758 773
61. A. Lutterotti et al., Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis Sci. Transl. Med. 2013 5 188ra175
62. S. Kontos I. C. Kourtis K. Y. Dane J. A. Hubbell Engineering antigens for in situ erythrocyte binding induces T-cell deletion Proc. Natl. Acad. Sci. U. S. A. 2013 110 E60 E68
63. T. K. Kishimoto R. A. Maldonado Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance Front. Immunol. 2018 9 230
64. D. R. Getts et al., Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis Nat. Biotechnol. 2012 30 1217 1224
65. Z. Hunter et al., A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease ACS Nano 2014 8 2148 2160
66. A. C. Shirali et al., Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival Am. J. Transplant. 2011 11 2582 2592
67. K. Ramani et al., Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A J. Pharm. Sci. 2008 97 1386 1398
68. I. Pujol-Autonell et al., Use of autoantigen-loaded phosphatidylserine-liposomes to arrest autoimmunity in type 1 diabetes PLoS One 2015 10 e0127057
69. R. A. Roberts et al., Towards programming immune tolerance through geometric manipulation of phosphatidylserine Biomaterials 2015 72 1 10
70. W. U. Kim et al., Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance Arthritis Rheum. 2002 46 1109 1120
71. S. Y. Min et al., Antigen-induced, tolerogenic CD11c+, CD11b+ dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis Arthritis Rheum. 2006 54 887 898
72. G. Cappellano et al., Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis Vaccine 2014 32 5681 5689
73. J. S. Lewis et al., A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice Clin. Immunol. 2015 160 90 102
74. J. J. Cho et al., An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis Biomaterials 2017 143 79 92
75. J. M. Gammon L. H. Tostanoski A. R. Adapa Y. C. Chiu C. M. Jewell Controlled delivery of a metabolic modulator promotes regulatory T cells and restrains autoimmunity J. Controlled Release 2015 210 169 178
76. K. A. Hlavaty X. Luo L. D. Shea S. D. Miller Cellular and molecular targeting for nanotherapeutics in transplantation tolerance Clin. Immunol. 2015 160 14 23
77. S. Jhunjhunwala G. Raimondi A. W. Thomson S. R. Little Delivery of rapamycin to dendritic cells using degradable microparticles J. Controlled Release 2009 133 191 197
78. A. Haddadi et al., Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells J. Biomed. Mater. Res., Part A 2008 84 885 898
79. R. A. Maldonado et al., Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance Proc. Natl. Acad. Sci. U. S. A. 2015 112 E156 E165
80. L. H. Tostanoski et al., Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen Specific Cell Rep. 2016 16 2940 2952
81. H. H. Lim et al., A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease Mol. Genet. Metab. Rep. 2017 13 18 22
82. A. H. Zhang R. J. Rossi J. Yoon H. Wang D. W. Scott Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation Cell. Immunol. 2016 301 74 81
83. T. K. Kishimoto et al., Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles Nat. Nanotechnol. 2016 11 890 899
84. K. J. Peine et al., Treatment of experimental autoimmune encephalomyelitis by codelivery of disease associated Peptide and dexamethasone in acetalated dextran microparticles Mol. Pharm. 2014 11 828 835
85. R. A. Meyer and J. J. Green, Artificial Antigen-Presenting Cells: Biomimetic Strategies for Directing the Immune Response, in Biomaterials in Regenerative Medicine and the Immune System, Springer, 2015, pp. 257-277
86. M. Oelke et al., Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells Nat. Med. 2003 9 619
87. J. W. Hickey F. P. Vicente G. P. Howard H.-Q. Mao J. P. Schneck Biologically inspired design of nanoparticle artificial antigen-presenting cells for immunomodulation Nano Lett. 2017 17 7045 7054
88. J. C. Sunshine K. Perica J. P. Schneck J. J. Green Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells Biomaterials 2014 35 269 277
89. R. A. Meyer et al., Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation Small 2015 11 1519 1525
90. A. Kosmides et al., Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma Biomaterials 2017 118 16 26
91. E. R. Steenblock T. M. Fahmy A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells Mol. Ther. 2008 16 765 772
92. E. R. Steenblock T. Fadel M. Labowsky J. S. Pober T. M. Fahmy An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response J. Biol. Chem. 2011 M111 276329
93. T. R. Fadel et al., A carbon nanotube-polymer composite for T-cell therapy Nat. Nanotechnol. 2014 9 639 647
94. C. Schütz et al., Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells Oncotarget 2016 7 68503
95. A. K. Kosmides J.-W. Sidhom A. Fraser C. A. Bessell J. P. Schneck Dual targeting nanoparticle stimulates the immune system to inhibit tumor growth ACS Nano 2017 11 5417 5429
96. L. Luo et al., Sustained release of anti-PD-1 peptide for perdurable immunotherapy together with photothermal ablation against primary and distant tumors J. Controlled Release 2018 278 87 99
97. J. Cano-Mejia et al., Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma. Nanomedicine: Nanotechnology Biol. Med. 2017 13 771 781
98. L. Tang et al., Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery Nat. Biotechnol. 2018 36 707
99. R. B. Jones et al., Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells Biomaterials 2017 117 44 53
100. L. D. Rhines et al., Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma Neurosurgery 2003 52 872 880
101. M. Chen H. Ouyang S. Zhou J. Li Y. Ye PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses Cell. Immunol. 2014 287 91 99
102. D. Schmid et al., T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity Nat. Commun. 2017 8 1747
103. H. Jonuleit E. Schmitt The regulatory T cell family: distinct subsets and their interrelations J. Immunol. 2003 171 6323 6327
104. M. R. Vieyra-Lobato J. Vela-Ojeda L. Montiel-Cervantes R. López-Santiago M. C. Moreno-Lafont Description of CD8+ Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer J. Immunol. Res. 2018 2018 3758713
105. L. Chatenoud J.-F. Bach Adaptive human regulatory T cells: myth or reality? J. Clin. Invest. 2006 116 2325 2327
106. Z. Chen et al., CD11c(high)CD8+ regulatory T cell feedback inhibits CD4 T cell immune response via Fas ligand-Fas pathway J. Immunol. 2013 190 6145 6154
107. P. Zaccone A. Cooke Harnessing CD8+ Regulatory T Cells: Therapy for Type 1 Diabetes? Immunity 2010 32 504 506
108. A. Moore J. Grimm B. Han P. Santamaria Tracking the Recruitment of Diabetogenic CD8 T-Cells to the Pancreas in Real Time Diabetes 2004 53 1459 1466
109. X. Wan et al., A Tolerogenic Artificial APC Durably Ameliorates Experimental Autoimmune Encephalomyelitis by Directly and Selectively Modulating Myelin Peptide-Autoreactive CD4+ and CD8+ T Cells. J. Immunol. 2018 201 1194 1210
110. W. Wang et al., A biodegradable killer microparticle to selectively deplete antigen-specific T cells in vitro and in vivo Oncotarget 2016 7 12176 12190
111. K. A. Hlavaty et al., Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation Biomaterials 2016 76 1 10
112. J. C. Sunshine K. Perica J. P. Schneck J. J. Green Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells Biomaterials 2014 35 269 277
113. E. Ben-Akiva R. A. Meyer D. R. Wilson J. J. Green Surface engineering for lymphocyte programming Adv. Drug Delivery Rev. 2017 114 102 115
114. X. Clemente-Casares et al., Expanding antigen-specific regulatory networks to treat autoimmunity Nature 2016 530 434 440
115. S. Tsai et al., Reversal of Autoimmunity by Boosting Memory-like Autoregulatory T Cells Immunity 2010 32 568 580
116. X. Xu et al., Multipeptide-coupled nanoparticles induce tolerance in 'humanised' HLA-transgenic mice and inhibit diabetogenic CD8+ T cell responses in type 1 diabetes Diabetologia 2017 2418 2431
117. H. Bruns et al., CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells Clin. Cancer Res. 2015 21 2075 2083
118. K. A. Shahzad et al., On-target and direct modulation of alloreactive T cells by a nanoparticle carrying MHC alloantigen, regulatory molecules and CD47 in a murine model of alloskin transplantation Drug Delivery 2018 25 703 715
119. B. M. Hall H. Waldmann T. K. Kishimoto R. A. Maldonado Nanoparticles for the induction of Antigen-Specific immunological Tolerance Front. Immunol. 2018 9 1
120. K. A. Hlavaty et al., Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation Biomaterials 2016 76 1 10
121. M. Look et al., Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice J. Clin. Invest. 2013 123 1741 1749
122. D. R. Getts L. D. Shea S. D. Miller N. J. C. King Harnessing nanoparticles for immune modulation Trends Immunol. 2015 36 419 427
123. M. D. McHugh et al., Paracrine co-delivery of TGF-beta and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells Biomaterials 2015 59 172 181
124. T. M. Fahmy, Nanoparticle-Mediated Delivery of Cytokines for Maintenance of the Regulatory T cell Phenotype, Yale University, US Pat., 0361265 A1, 2016
125. J. Park et al., Modulation of CD4+ T Lymphocyte Lineage Outcomes with Targeted, Nanoparticle-Mediated Cytokine Delivery Mol. Pharm. 2011 8 143 152
126. C. Schütz et al., Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells Blood 2008 111 3546 3552
127. C. Shen et al., Killer artificial antigen-presenting cells deplete alloantigen-specific T cells in a murine model of alloskin transplantation Immunol. Lett. 2011 138 144 155
128. W. Wang et al., An Antigen-Presenting and Apoptosis-Inducing Polymer Microparticle Prolongs Alloskin Graft Survival by Selectively and Markedly Depleting Alloreactive CD8+ T Cells Front. Immunol. 2017 8 657
129. S. V. Desiderio B-cell activation Curr. Opin. Immunol. 1992 4 252 256
130. N. E. Harwood F. D. Batista Early events in B cell activation Annu. Rev. Immunol. 2009 28 185 210
131. V. V. Temchura D. Kozlova V. Sokolova K. Überla M. Epple Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles loaded with protein antigen Biomaterials 2014 35 6098 6105
132. J. Ingale et al., High-density array of well-ordered HIV-1 spikes on synthetic liposomal nanoparticles efficiently activate B cells Cell Rep. 2016 15 1986 1999
133. N. R. Bennett D. B. Zwick A. H. Courtney L. L. Kiessling Multivalent antigens for promoting B and T cell activation ACS Chem. Biol. 2015 10 1817 1824
134. A. Sicard et al., B cells loaded with synthetic particulate antigens: a versatile platform to generate antigen-specific helper T cells for cell therapy Nano Lett. 2015 16 297 308
135. A. Francian K. Mann M. Kullberg Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs Int. J. Nanomed. 2017 12 5149
136. S. Y. Tzeng et al., Stabilized single-injection inactivated polio vaccine elicits a strong neutralizing immune response Proc. Natl. Acad. Sci. U. S. A. 2018 115 E5269 E5278
137. J. M. Carreño et al., PLGA-microencapsulation protects Salmonella typhi outer membrane proteins from acidic degradation and increases their mucosal immunogenicity Vaccine 2016 34 4263 4269
138. N. Manjarrez-Orduño T. D. Quách I. Sanz B cells and immunological tolerance J. Invest. Dermatol. 2009 129 278 288
139. M. S. Macauley et al., Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis J. Clin. Invest. 2013 123 3074 3083
140. B. H. Duong et al., Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo J. Exp. Med. 2010 207 173 187
141. L. Pang M. S. Macauley B. M. Arlian C. M. Nycholat J. C. Paulson Encapsulating an Immunosuppressant Enhances Tolerance Induction by Siglec-Engaging Tolerogenic Liposomes ChemBioChem 2017 18 1226 1233
142. R. Kirnbauer F. Booy N. Cheng D. R. Lowy J. T. Schiller Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic Proc. Natl. Acad. Sci. U. S. A. 1992 89 12180 12184
143. B. Chackerian D. R. Lowy J. T. Schiller Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies J. Clin. Invest. 2001 108 415 423
144. D. R. Shook D. Campana Natural killer cell engineering for cellular therapy of cancer Tissue Antigens 2011 78 409 415
145. K. D. Moynihan et al., Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses Nat. Med. 2016 22 1402
146. C. J. Denman et al., Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells PLoS One 2012 7 e30264
147. X. Xu et al., Liver sinusoidal endothelial cells induce tolerance of autoreactive CD4+ recent thymic emigrants Sci. Rep. 2016 6 19861
148. A. Carambia, et al., Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice, 2015
149. M. O. Oyewumi A. Kumar Z. Cui Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses Expert Rev. Vaccines 2010 9 1095 1107